Sarah Burns – Managing Director

A year of achievements and growth: Medica 2023 round-up:

As we bid farewell to another eventful year, I am thrilled to reflect on the remarkable progress and achievements that Medica has experienced throughout 2023. The dedication and hard work of our team, combined with strategic moves and partnerships, have positioned us for an even more exciting future. Join me as we take a journey through the key highlights of the year.

 Expanding horizons: JCA Seminars acquisition

At the beginning of the year, we embarked on a significant venture by acquiring JCA Seminars. This strategic move not only broadened our offerings but also paved the way for collaboration and growth. Over the next 12 months, we are committed to developing and extending their capabilities. Keep an eye out for exciting opportunities for reporters to engage and leverage JCA Seminars for CPD. The coming year promises new educational events and products that will shape the landscape in 2024 and beyond.

Embracing change: Medica’s acquisition by IK Partners

In July, Medica underwent a transformative change as IK Partners acquired the company, leading to our delisting from the London Stock Exchange. It is essential to note that this change is not a deviation from our direction and governance but, rather, an endorsement of our strengths and commitment to sustained growth and evolution.

 A new era of reporting: MedConnect

November marked a significant milestone with the launch of Medica’s new reporting platform, MedConnect. Featuring HL-7 integration and some additional in house developed features, this will increase efficiency for both our reporters and hospitals, saving time and resource. We anticipate making this widely available as part of our offering in 2024.

 New service launched: MedPath digital histopathology reporting

Also in November, we celebrated the grand opening of our new digital pathology reporting hub in Runcorn, Cheshire—now the home of MedPath, our digital histopathology reporting service. Just last week, we celebrated the successful launch of phase 1 in the MedPath service line. Offering a comprehensive digital histopathology service that includes routine and specialist reporting, along with full management, MedPath is poised for success. We look forward to extending this service to clients in the coming year.

Global reach: expanding the number of overseas reporters

Throughout 2023, we witnessed a surge in the number of overseas reporters joining Medica from India, Europe, Australasia, and the UAE. This expansion is not only a testament to our global impact but also an exciting avenue for further growth. As we move forward, we remain committed to nurturing and expanding our reporter base in these regions.

In closing, I want to express my gratitude to everyone who has contributed to Medica’s success in 2023. Your dedication, passion, and collaborative spirit have fuelled our achievements, and I am confident that the coming year holds even greater promise. Happy new year everybody!

 

Sarah Burns – Medica UK Managing Director